Efek Samping Hematologi Akibat Kemoterapi dan Tatalaksananya

Anna Febriani, Yuly Rahmawati

= http://dx.doi.org/10.20473/jr.v5-I.1.2019.22-28
Abstract views = 704 times | downloads = 5762 times

Abstract


Lung cancer is the leading cause of cancer death in Asia. In Indonesia, it contributes the highest number to cancer incidence in male and is ranked fifth in female cancer incidence. Determinated attempts have been delivered to eliminate cancer with chemotherapy being the most important management strategy for advance stage lung cancer.

As most medicines come with side effects, so does chemotherapy. Beside killing the target cells, the cytotoxic compound of cancer drug may also seriously alter normal cells. Therefore, formidable toxic effect of chemotherapy to normal tissue becomes the main problem, which clinicians should consider. Myelotoxicity is one of the most common chemotherapy-induced adverse events. It takes place in bone marrow-producing regions causing netropenia, thrombocytopenia and anemia. Each of those cytopenias requires separate intervention.  This article will review the physiology of hematopoiesis, pathophysiology of cytopenias, and current guidelines and recommendations for prevention and treatment of myelotoxicity of cytotoxic chemotherapy.


Keywords


lung cancer, adverse event, myelotoxicity, management

Full Text:

PDF

References


International Agency for Research on Cancer. Latest Global Cancer Data. Geneva: 2018.

Didkowska J, Wojciechowska U, Mańczuk M, Łobaszewski J. Lung cancer epidemiology : contemporary and future challenges worldwide. Ann Transl Med 2016;4(2):1–11.

Komite Penanggulangan Kanker Nasional. Pedoman Nasional Pelayanan Kedokteran : Kanker Paru. Jakarta: Kementrian Kesehatan Republik Indonesia; 2018.

Research Institute of Nursing Care for People and Community (RINCPC). Handbook of Self-Managing Side Effects of Chemotherapy in Times of Disaster. In: Disaster Nursing in a Ubiquitous Society Care. Hyogo: University of Hyogo; 2006.

Poehlmann J. Comparing Chemotherapy, Targeted Therapy, and Immunotherapy [Internet]. 2018 [cited 2018 Oct 13];Available from: https://lungcancer.net/clinical/comparing-treatments/

Chabner BA, Amrein PC, Druker BJ, et al. Chemotherapy of Neoplastic Diseases. In: Brunton L, Chabner B, Knollmann B, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. New York: The McGraw-Hill Companies; 2011. p. 1854–1921.

Ponzoni M. Liposomal Chemotherapy. Encycl. cancer. 2011;2059.

Arora A, Scholar EM. Role of Tyrosine Kinase Inhibitors in Cancer Therapy. J Pharmacol Exp Ther 2005;315(3):971–979.

Hoffbrand A, Moss P, Pettit J. Essential Haematology. 5th ed. Victoria: Blackwell Publishing; 2006.

Balducci L, Shah B, Zuckerman K. Netropenia and Thrombocytopenia. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer : Principles and Practice of Oncology. Philadelphia: Wolters Kluwer Health; 2015. p. 1960–1967.

Gatti DM, Weber SN, Goodwin NC, Lammert F, Churchill GA. Genetic background influences susceptibility to chemotherapy-induced hematotoxicity. Pharmacogenomics J [Internet] 2017;00(June):1–12. Available from: http://dx.doi.org/10.1038/tpj.2017.23

Common Terminology Criteria for Adverse Events ( CTCAE ). 5.0. US Department of Health and Human Services; 2017.

Jin H, Chen X, He W, Liu Q, Wei Z, Li J. Risk Factors for Chemotherapy-Induced Leukopenia in Patients with Lung Cancer. Int J Clin Med 2016;7(March):225–230.

Shukla P, Singh R. Potential pharmacological interventions against hematotoxicity : an overview. Expert Rev Hematol 2015;1–10.

Kurtin S. Myeloid Toxicity of Cancer Treatment. J Adv Pr Oncol 2012;3(4):209–224.

Natarajan SK, Narayan S, Yin JAL. Update on the Management of Febrile Netropenia. Eur Oncol Haematol 2011;7(4):263–269.

Kuter DJ. Managing Thrombocytopenia Associated With Cancer Chemotherapy. Cancer Netw 2015;29(4):1–11.

Silva E De, Kim H. Thrombocytopenia : Focus on platelet apoptosis. Chem Biol Interact [Internet] 2018;284:1–11. Available from: https://doi.org/10.1016/j.cbi.2018.01.015

Aldoss IT, Wilson S, Silberstein PT. Chemotherapy-induced Anaemia. 2008;24–26.

Lyman G, Glaspy J. Advances in the Management of Chemotherapy-Induced Anemia and Its Treatment. Oncol J 2006;20(8):1517–1525.

Myeloid Growth Factors. In: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). National Comprehensive Cancer Network, Inc.; 2014.

Sausville E, Longo D. Principles of Cancer Treatment. In: Longo DL, editor. Harrison’s Hematology and Oncology. New York: McGraw-Hill Education; 2017. p. 418.

Newman BT. What’s to know about netropenia ? [Internet]. Netropenia Causes, diagnosis, Treat. 2018 [cited 2018 Aug 17];1–8. Available from: https://www.medicalnewstoday.com/articles/265373.php

Psaila B, Bussel JB. Recent Insights Into Chemotherapy-Induced Thrombocytopenia [Internet]. 2007 [cited 2018 Aug 17];1–5. Available from: https://www.medscape.org/viewarticle/555566_prin

Rodgers GM, Becker PS, Blinder M, Chanan-Khan A. Cancer- and Chemotherapy- Induced Anemia : Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 2012;10(5):628–653.

Kurbatova P, Pujo-menjouet L. Multi-Agent Systems and Blood Cell Formation. In: Modeling, Interactions, Simulations and Case Studies. ResearchGate; 2011. p. 395.

Guidelines for the Management of Chemotherapy and Systemic Anticancer Therapy Induced Toxicities Within Primary Care ( Adult solid tumour oncology and Adult haemato-oncology ) “ Quality and safety for every patient every time .” In: NECN Guidelines for Community Management of Chemotherapy Toxicity. Gateshead: North of England Cancer Network; 2011. p. 0–21.


Refbacks

  • There are currently no refbacks.




View My Stats

INDEXED BY:

    
      

Creative Commons License

JR (p-ISSN: 2407-0831e-ISSN: 2621-8372) is licensed under Creative Commons Attribution-ShareAlike 4.0 International License.